Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

CLARIFICATION ANNOUNCEMENT

PLACING OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcement of the Company dated 21 August 2025, in relation to, among other things, the placing agreement entered into by the Company with CNI Securities Group Limited as the placing agent dated 21 August 2025 for up to 145,000,000 placing shares of the Company at the placing price of HK$0.415 per placing share (the "**Announcement**"). Unless otherwise specified, the terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Company noted an inadvertent clerical error in the Announcement and wishes to clarify that the General Mandate will not be fully utilised upon allotment and issue of all the Placing Shares. However, such General Mandate granted to the Directors on 29 August 2024 has expired at the conclusion of the annual general meeting of the Company held on 29 August 2025.

Save as disclosed above, all other information and contents set out in the Announcement shall remain unchanged. This clarification announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 29 August 2025

As at the date of this announcement, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director), and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.ipb.asia and www.irasia.com/listco/hk/ipb.